Csenge Advisory Group Has $759,000 Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)


Share on StockTwits

Csenge Advisory Group cut its position in Bristol-Myers Squibb (NYSE:BMY) by 4.8% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,121 shares of the biopharmaceutical company’s stock after selling 609 shares during the period. Csenge Advisory Group’s holdings in Bristol-Myers Squibb were worth $759,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BMY. Retirement Group LLC bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $27,000. Orion Capital Management LLC bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $28,000. Perennial Advisors LLC bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $29,000. Brand Asset Management Group Inc. bought a new stake in shares of Bristol-Myers Squibb during the first quarter worth $31,000. Finally, Founders Capital Management bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $31,000. Institutional investors own 72.41% of the company’s stock.

Shares of Bristol-Myers Squibb stock opened at $63.48 on Tuesday. Bristol-Myers Squibb has a twelve month low of $54.07 and a twelve month high of $67.16. The company has a quick ratio of 1.58, a current ratio of 1.67 and a debt-to-equity ratio of 0.82. The company has a 50-day simple moving average of $63.60 and a two-hundred day simple moving average of $63.04. The stock has a market capitalization of $141.81 billion, a price-to-earnings ratio of -577.04, a price-to-earnings-growth ratio of 1.00 and a beta of 0.67.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Wednesday, April 28th. The biopharmaceutical company reported $1.74 earnings per share for the quarter, missing the consensus estimate of $1.82 by ($0.08). Bristol-Myers Squibb had a positive return on equity of 27.48% and a negative net margin of 0.11%. The business had revenue of $11.07 billion during the quarter, compared to analyst estimates of $11.19 billion. During the same quarter last year, the firm earned $1.72 EPS. Bristol-Myers Squibb’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Bristol-Myers Squibb will post 6.35 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Monday, May 3rd. Shareholders of record on Thursday, April 1st were issued a $0.49 dividend. This represents a $1.96 annualized dividend and a yield of 3.09%. The ex-dividend date of this dividend was Wednesday, March 31st. Bristol-Myers Squibb’s dividend payout ratio is currently 41.79%.

In other Bristol-Myers Squibb news, CEO Giovanni Caforio sold 25,000 shares of the firm’s stock in a transaction dated Monday, March 22nd. The shares were sold at an average price of $62.20, for a total value of $1,555,000.00. Following the transaction, the chief executive officer now directly owns 528,980 shares of the company’s stock, valued at approximately $32,902,556. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.14% of the stock is owned by company insiders.

BMY has been the subject of several research reports. Truist raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Tuesday, April 13th. Truist Securities raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and raised their target price for the company from $66.00 to $74.00 in a research report on Monday, April 19th. Morgan Stanley downgraded shares of Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $70.00 to $62.00 in a research report on Friday. Truist Financial raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Tuesday, April 13th. Finally, Zacks Investment Research raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a research report on Tuesday, April 6th. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $73.81.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.

See Also: Why is a lock-up period needed for an IPO?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.